Due to the pivotal role of mitochondria in the generation of adenosine triphosphate (ATP) and the regulation of cellular homeostasis, mitochondrial dysfunction may exert a profound impact on various physiological systems, potentially precipitating a spectrum of distinct diseases. Consequently, research pertaining to mitochondrial therapeutics has assumed increasing significance, warranting heightened scrutiny. In recent years, the field of mitochondrial therapy has witnessed noteworthy advancements, with active exploration into diverse pharmacological agents aimed at ameliorating mitochondrial function. Elamipretide (SS-31), a novel synthetic mitochondrial-targeted antioxidant, has emerged as a promising candidate with extensive therapeutic potential. Its notable attributes encompass the mitigation of oxidative stress, the suppression of inflammatory processes, the maintenance of mitochondrial dynamics, and the prevention of cellular apoptosis. As such, SS-31 may emerge as a viable choice for the treatment of mitochondrial dysfunction-related ailments in the foreseeable future. This article extensively expounds upon the superiority of SS-31 over natural antioxidants and traditional mitochondrial-targeted antioxidants, delves into its mechanisms of modulating mitochondrial function, and comprehensively summarizes its applications in alleviating mitochondrial dysfunction-associated disorders. Furthermore, we offer a comprehensive outlook on the expansive prospects of SS-31′s future development and application.

中文翻译：

---

新型多肽线粒体靶向抗氧化剂SS-31在减轻线粒体功能障碍中的应用研究

由于线粒体在三磷酸腺苷 (ATP) 的生成和细胞稳态调节中的关键作用，线粒体功能障碍可能对各种生理系统产生深远的影响，可能引发一系列不同的疾病。因此，与线粒体治疗相关的研究变得越来越重要，需要加强审查。近年来，线粒体治疗领域取得了显着的进展，积极探索旨在改善线粒体功能的多种药物。Elamipretide (SS-31) 是一种新型合成线粒体靶向抗氧化剂，已成为具有广泛治疗潜力的有前途的候选药物。其显着的特性包括减轻氧化应激、抑制炎症过程、维持线粒体动力学和预防细胞凋亡。因此，在可预见的未来，SS-31 可能成为治疗线粒体功能障碍相关疾病的可行选择。本文广泛阐述了SS-31相对于天然抗氧化剂和传统线粒体靶向抗氧化剂的优越性，深入探讨了其调节线粒体功能的机制，并全面总结了其在缓解线粒体功能障碍相关疾病中的应用。此外，我们对SS-31未来发展和应用的广阔前景进行了全面展望。